Document:

Exhibit 10.21

 

FIFTH AMENDMENT, WAIVER AND CONSENT

 

This Fifth Amendment,
Waiver and Consent (“Fifth Consent”) is made and entered into as of July 15 , 2016, by and among Accelerated Pharma,
Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Purchaser”
and collectively, “Purchasers”). Capitalized terms used but not defined herein will have the meanings assigned to them
in the Securities Purchase Agreements and Transaction Documents (as defined below). Capitalized terms defined herein shall be incorporated
in the Transaction Documents, as appropriate.

 

WHEREAS, the Company
and Purchasers identified on Schedule A entered into Securities Purchase Agreements (“Securities Purchase Agreements”)
and other Transaction Documents (collectively, “Transaction Documents”) dated as of December 23, 2014, May 8, 2015,
June 11, 2015, November 6, 2015, April 20, 2016, April 22, 2016, May 9, 2016 and May 27, 2016; and

 

WHEREAS, the Transaction
Documents were previously amended and certain consents and waivers were granted pursuant to a certain Amendment, Waiver and Consent
entered into as of May 8, 2015 and as further amended on November 6, 2015 pursuant to a Second Amendment, Waiver and Consent and
as further amended on April 20, 2016 pursuant to a Third Amendment, Waiver and Consent and as further amended on May 9, 2016 pursuant
to a Fourth Amendment, Waiver and Consent; and

 

WHEREAS, the Company
issued to the Purchasers Secured Convertible Notes (“Notes”) and Warrants (the “Warrants”); and

 

WHEREAS, the Company
wishes to amend the definition of Termination Date as it is employed in the Securities Purchase Agreements and Transaction Documents
to allow additional Closings for the balance of the maximum allowed Subscription Amount to occur until September 1, 2016 instead
of June 30, 2016 as well as to increase the maximum allowed Subscription Amount from $1,500,000 to up to $2,000,000; and

 

WHEREAS, the Company
and Purchasers agree to the following amendments, waivers, and consents, which amendments, waivers and consents shall be effective,
the approval of a Majority in Interest which shall be binding on all Purchasers (“Effective Date”).

 

NOW, THEREFORE, the
Company and Purchasers hereby agree as follows:

 

1.          The
term “Termination Date” and the maximum allowed Subscription Amount as both are defined in Section 2.1 of the Securities
Purchase Agreements shall mean September 1, 2016 and $2,000,000, respectively.

 

2.          The
undersigned represents to the Company that it is the holder of the Notes and Warrants in the amounts set forth on Schedule A
hereto, it has not sold, transferred or otherwise assigned any of the Notes and Warrants and it has the authority to enter into
and deliver this Consent.

 

3.          The
Company represents that Schedule A hereto identifies all of the holders and sets forth the amounts as of the date herein
of all of the securities issued or issuable pursuant to the Securities Purchase Agreements and that the Transaction Documents have
not been previously amended nor any waiver of any term thereof granted by any party thereto other than as set forth in the Amendment
Waiver and Consent, the Second Amendment, Waiver and Consent, the Third Amendment, Waiver and Consent, the Fourth Amendment, Waiver
and Consent and this Fifth Consent.

 

    	 	1	 

     

    

 

 

4.          This
Fifth Consent may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute
one and the same instrument. This Fifth Consent may be signed and delivered by facsimile or electronically and such facsimile or
electronically signed and delivered Fifth Consent shall be enforceable.

 

5.          This
Fifth Consent shall be included in the definition of Transaction Documents as such term is defined in the Securities Purchase Agreements.

 

6.          Sections
5.4, 5.5, 5.12 and 5.21 of the Securities Purchase Agreements are incorporated herein by reference.

 

7.          Except
as expressly set forth herein, this Fifth Consent shall not be deemed to be a waiver, amendment or modification of any provisions
of the Transaction Documents or of any right, power or remedy of the Purchaser, or constitute a waiver of any provision
of the Transaction Documents (except to the extent herein set forth), or any other document, instrument and/or agreement executed
or delivered in connection therewith and any other agreement to which the Purchaser may be parties to, in each case whether arising
before or after the date hereof or as a result of performance hereunder or thereunder. Except as set forth herein, the Purchaser
reserves all rights, remedies, powers, or privileges available under the Transaction Documents and any other agreement to
which the Purchaser may be parties to, at law or otherwise. This Fifth Consent shall not constitute a novation or satisfaction
and accord of the Transaction Documents or any other document, instrument and/or agreement executed or delivered in connection
therewith and any other agreement to which the Purchaser may be a party to.

 

(Signatures to follow)

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the Company and the
undersigned Purchasers have caused this Fifth Consent to be executed as of the date first written above.

 

	 	ACCELERATED PHARMA, INC.
	 	the “Company”
	 	 	 
	 	By:	 

 

“PRIOR
PURCHASER”

 

Name of Prior Purchaser:
____________________________________________________________________________

 

Signature of Authorized Signatory of
Prior Purchaser: ______________________________________________________

 

Name of Authorized Signatory: _______________________________________________________________________

 

Title of Authorized Signatory: ________________________________________________________________________

 

    	 	3	 

     

    

 

Exhibit A

List of Prior Purchasers

 

SCHEDULE A

 

	PURCHASERS OF DECEMBER 23, 2014	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	CURBER INTERNATIONAL LTD.
 William House, 2nd Floor
 Hibiscus Square, Pond Street
 P.O. Box 156
 Grand Turk Truks and Caicos Island
 Attn: M. Goldschmid
 Mgoldshmid48@gmail.com
	 	$	400,000.00	 	 	 	27,778	 
	MORRIS FUCHS
 1109 East 22nd Street
 Brooklyn, New York 11210
 Email: lenoxxmorris@aol.com
	 	$	50,000.00	 	 	 	3,472	 
	NACHUM STEIN
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	100,000.00	 	 	 	6,944	 
	AMERICAN EUROPEAN INSURANCE CO.
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	100,000.00	 	 	 	6,944	 
	HSI PARTNERSHIP
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	50,000.00	 	 	 	3,472	 
	RR INVESTMENT 2012 LP
 c/o Ken Gliedman
 Licht Gliedman Investments PC
 551 5th Avenue
 New York, NY 10176
	 	$	50,000.00	 	 	 	3,472	 
	TOTALS	 	$	750,000.00	 	 	 	 	 

 

    1 

     

    

SCHEDULE A (continued)

 

	PURCHASERS OF MAY 8, 2015 AND JUNE 11, 2015	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	2004 LEON SCHARF IRREVOCABLE TRUST CORP. 
3839 Flatlands Ave., Suite 201 
Brooklyn, NY 11234 
Attn: Willy Beer 
Tax ID# 20-665-6152	 	$	100,000.00	 	 	 	50,000	 
	HOCH FAMILY EQUITIES LLC 
125-10 Queens Boulevard, Suite 224 
Kew Gardens, NY 11415 
Attn: Joseph Hoch, Member 
Tax ID# 263694206	 	$	50,000.00	 	 	 	25,000	 
	RR INVESTMENT 2012 LP 
285 Central Park West 
New York, NY 10024 
Attn: Ralph Rieder, Manager 
Tax ID# 30-0759589	 	$	500,000.00	 	 	 	250,000	 
	API BIO INVESTORS, LLC 
7 Glenwood Avenue, Suite 4190 
East Orange, NJ 07017 
Attn: AJ Ginsburg, Member 
AJginsburg12@gmail.com 
Tax ID# 47-3876371	 	$	340,000.00	 	 	 	170,000	 
	ABRAHAM BELSKY 
16 Boxwood Lane 
Lawrence, NY 11559 
Fax: 718 313-9880 
Tax ID# ###-##-####	 	$	50,000.00	 	 	 	25,000	 
	EDWIN W. COLMAN CHILDREN’S TRUST 
50 Adams Gulch Road 
Ketchum, ID 83340 
Attn: Robert S. Colman, Trustee 
Email: bcolman@colman-partners.com 
Tax ID# 39-6330570	 	$	100,000.00	 	 	 	50,000	 
	ELI INZLICHT-SPREI
 1121 East 21st Street
 Brooklyn, NY 11210
 Fax: 718-859-5717
 Tax ID# ###-##-####
	 	$	25,000.00	 	 	 	12,500	 
	HARVEY LANG 
783 Montgomery Street 
Brooklyn, NY 11213 
Fax: 718-773-1283 
Tax ID# ###-##-####	 	$	25,000.00	 	 	 	12,500	 
	ALPHA CAPITAL ANSTALT 
Lettstrasse 32 
9490 Vaduz, Liechtenstein 
Attn: Konrad Ackermann, Director 
Fax: 011-423-2323196	 	$	750,000.00	 	 	 	375,000	 
	BRIO CAPITAL MASTER FUND LTD. 
C/O Brio Management LLC 
100 Merrick Road, Suite 401C 
Rockville Centre, NY 11570-4800 
Fax: 646-390-2158 
Tax ID# 98-1072321	 	$	110,000.00	 	 	 	55,000	 
	BERNHARD LAZARUS
 42 Herbert Samuel St., Apt. 40
 Tel Aviv 68018, Israel
 Email: lazarusb@netvision.net.il
 Tax ID#: ###-##-####
	 	$	50,000.00	 	 	 	25,000	 
	TOTALS	 	$	2,100,000.00	 	 	 	1,050,000	 

 

    2 

     

    

 

SCHEDULE A (continued)

 

	PURCHASERS OF NOVEMBER 6, 2015	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	API BIO INVESTORS, LLC 
1 Skyline Terrace 
Spring Valley, NY 10977 
Attn:
    A.J. Ginsburg, Member 
Email: AJGinsburg12@gmail.com 
Tax ID#:	 	$	220,000.00	 	 	 	6,659	 
	MORDECHAI MARC BELSKY 
270 Forest Avenue 
Woodmere, NY 11598 
Tel.: (516) 375-6000 
Tax ID# ###-##-####	 	$	50,000.00	 	 	 	1,513	 
	KEREN BROCHA 
26 Commonwealth Drive 
Lakewood, NJ 08701 
Attn: Chaim Stefansky, Manager 
Tel.: (718) 362-1634 
Tax ID#: 32-0012556	 	$	35,000.00	 	 	 	1,059	 
	CHAIM GROSS 
1980 Swarthmore Avenue, Unit 1 
Lakewood, NJ 08701 
Tel.: (732) 930-9805 
Tax ID#: ###-##-####	 	$	30,000.00	 	 	 	908	 
	HOCH FAMILY EQUITIES, LLC 
125-10 Queens Boulevard, Suite 224 
Kew Gardens, NY 11415 
Attn: Ari Hoch, Member 
Fax: (718) 374-3872 
Tax ID# 26-3694206	 	$	100,000.00	 	 	 	3,027	 
	MORRIS FUCHS
 1109 East 22nd Street
 Brooklyn, New York 11210
 Email:
                                         gcmf47@gmail.com
	 	$	50,000.00	 	 	 	1,513	 
	ELI INZLICHT-SPREI
 1121 East 21st Street
 Brooklyn, NY 11210
 Fax: 718 859-5717
 Tax ID# ###-##-####
	 	$	15,000.00	 	 	 	454	 
	TOTALS	 	$	500,000.00	 	 	 	15,133	 

 

    3 

     

    

 

SCHEDULE A (continued)

 

	PURCHASERS OF APRIL 20, 2016 and APRIL 22, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	2004 LEON SCHARF IRREVOCABLE TRUST CORP. 
3839 Flatlands Ave., Suite 201 
Brooklyn, NY 11234 
Attn: Willy Beer 
Tax ID# 20-665-6152	 	$	100,000.00	 	 	 	2,579	 
	VENTURE CAP GROUP LLC 
730 Eastern Parkway 
Brooklyn, NY 11213	 	$	50,000.00	 	 	 	1,289	 
	NACHUM STEIN
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	40,000.00	 	 	 	1,031	 
	AMERICAN EUROPEAN INSURANCE CO.
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	40,000.00	 	 	 	1,031	 
	HSI PARTNERSHIP
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	20,000.00	 	 	 	516	 
	TOTALS	 	$	250,000.00	 	 	 	6,446	 

 

	PURCHASERS OF MAY 9, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	MANUEL S. SCHARF
 1575 50th Street, Suite 201
 Brooklyn, New York 11219
 Fax: (718) 853-5757
	 	$	100,000.00	 	 	 	2,579	 

 

	PURCHASERS OF MAY 27, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	SCHEIN VENTURES LLC 
552 Clubhouse Road 
Woodmere, New York 11598 
Attn: Joshua D. Schein, Manager	 	$	100,000.00	 	 	 	2,149	 

 

	PURCHASERS OF MAY 27, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE
	 	 	WARRANTS	 
	Yuri Rabinovich 
200 E. Delaware PL, Unit 4C 
Chicago, IL 60611	 	$	50,000.00	 	 	 	1,074	 
	Ross Overbeek 
6317 New Albany Road 
Lisle, IL 60532	 	 	20,000	 	 	 	430	 

 

    4Exhibit 10.22

 

AMENDED AND RESTATED FIFTH AMENDMENT,
WAIVER AND CONSENT

 

This Amended and Restated
Fifth Amendment, Waiver and Consent (“Amended Fifth Consent”) which supersedes the Fifth Amendment, Waiver and Consent
entered into on July 15, 2016, is made and entered into as of September 20, 2016, by and among Accelerated Pharma, Inc., a Delaware
corporation (the “Company”), and the parties identified on the signature page hereto (each a “Purchaser”
and collectively, “Purchasers”). Capitalized terms used but not defined herein will have the meanings assigned to them
in the Securities Purchase Agreements and Transaction Documents (as defined below). Capitalized terms defined herein shall be incorporated
in the Transaction Documents, as appropriate.

 

WHEREAS, the Company
and Purchasers identified on Schedule A entered into Securities Purchase Agreements (“Securities Purchase Agreements”)
and other Transaction Documents (collectively, “Transaction Documents”) on dates ranging from December 2014 through
September 2016 (the Securities Purchase Agreements executed in 2016 are collectively known as the “2016 Securities Purchase
Agreements”); and

 

WHEREAS, the Transaction
Documents were previously amended and certain consents and waivers were granted pursuant to a certain Amendment, Waiver and Consent
entered into as of May 8, 2015 (the “First Amendment”) and as further amended on November 6, 2015 pursuant to a Second
Amendment, Waiver and Consent (the “Second Amendment”) and as further amended on April 20, 2016 pursuant to a Third
Amendment, Waiver and Consent (the “Third Amendment”) and as further amended on May 9, 2016 pursuant to a Fourth Amendment,
Waiver and Consent (the “Fourth Amendment”) and as further amended on July 15, 2016 pursuant to a Fifth Amendment,
Waiver and Consent (the “Fifth Amendment”, and together with the First Amendment, Second Amendment, Third Amendment,
and Fourth Amendment, the “Prior Amendments”); and

 

WHEREAS, pursuant to
the Transaction Documents, the Company issued to the Purchasers Secured Convertible Notes (“Notes”) and Warrants (the
“Warrants”); and

 

WHEREAS, the Company
wishes to amend the definition of Qualified Offering as it is defined in Section 1.1 of the 2016 Securities Purchase Agreements
and the accompanying Transaction Documents and as amended pursuant to the Prior Amendments; and

 

WHEREAS, the Company
wishes to amend the definition of Termination Date as it is employed in the 2016 Securities Purchase Agreements and the accompanying
Transaction Documents to the 2016 Securities Purchase Agreements to allow additional Closings for the balance of the maximum allowed
Subscription Amount to occur until October 5, 2016 instead of June 30, 2016 as well as to increase the maximum allowed Subscription
Amount from $1,500,000 to up to $1,850,000; and

 

WHEREAS, the Company
is requesting that Purchasers waive any Events of Default that occurred or may have occurred prior to the date hereof and for a
future period of time; and

 

WHEREAS, the Company
is requesting that the Purchasers of the Notes (“December 2014 Purchasers”) issued on December 23, 2014 (“December
2014 Notes”) agree to the extension of the Maturity Date of the December 2014 Notes to November 30, 2016, and in connection
with the consent of such extension of the Maturity Date by the December 2014 Purchasers,, the Company agrees to issue to the December
2014 Purchasers an aggregate of 5,208 Warrants; and

 

    	 	1	 

     

    

 

WHEREAS, the Company
is requesting that the Purchasers agree to the amendment of the Notes to delete Section 6(a) – Mandatory Exchange and delete
Section 6(b) – Optional Redemption and add Section 4(a)(ii) – Automatic Conversion as well as the addition of certain
registration rights; and

 

WHEREAS, the Company
and Purchasers agree to the following amendments, waivers, and consents, which amendments, waivers and consents shall be effective
upon the approval of all Purchasers (“Effective Date”).

 

NOW, THEREFORE, the
Company and Purchasers hereby agree as follows:

 

1.          The
definition of “Qualified Offering” in Section 1.1 of the Securities Purchase Agreements is deleted and replaced with
the following:

 

““Qualified Offering”
means the occurrence of an offering of the Company’s Common Stock which closes in one or more closings in connection with
which the Company receives not less than $5,000,000 of gross cash proceeds from the sale of Common Stock on or before November
30, 2016 at a pre-money valuation on a fully diluted basis of at least $20,000,000.”

 

2.          The
term “Termination Date” and the maximum allowed Subscription Amount as both are defined in Section 2.1 of the 2016
Securities Purchase Agreements shall mean September 30, 2016 and $1,850,000, respectively.

 

3.          The
Maturity Date of the December 2014 Notes is extended to November 30, 2016.

 

4.          Purchasers
waive any Events of Default that have occurred or may have occurred prior to the date hereof and agree to continue to waive any
such default or defaults through November 30, 2016 (the period from the date hereof through November 30, 2016 being referred to
as the “Waiver Period”) in order to afford the Company the opportunity to implement a Qualified Offering.

 

5.          Section
4(a) has been amended to add Section 4(a)(ii) as follows:

 

“Automatic Conversion.
Upon the closing of a Qualified Offering, all of the outstanding principal amount, plus any accrued but unpaid interest, hereunder
shall automatically convert into the same type of securities offered in the Qualified Offering at the then in effect Conversion
Price; provided, however, that if such closing of the Qualified Offering occurs following the end of the Waiver Period,
there shall be no automatic conversion if, at such time, an Event of Default has occurred (but has not been cured, if subject
to cure), is then occurring or if there is an existing event which, with the passage of time or the giving of notice, would
constitute an Event of Default. The Holder shall, within three (3) calendar days of receiving notice from the Company of the anticipated
closing of a Qualified Offering, deliver to Borrower (i) a Notice of Conversion requesting conversion of all of the outstanding
principal and accrued but unpaid interest on the Note and (ii) the original Note. In the event that the Holder does not deliver
a Notice of Conversion within three (3) calendar days of receiving notice of a Qualified Offering, the Holder acknowledges and
agrees that the Borrower shall have the right to cancel the Note in its entirety and send to the Holder the number of securities
that would otherwise have been issued to the Holder in connection with this Section 4(a)(ii).”

 

    	 	2	 

     

    

 

6.          Section
6 of the Notes is deleted in its entirety and replaced with the following:

 

“Registration Rights.
If the Company consummates an initial public offering of its Common Stock and such initial public offering is a Qualified Offering,
then the Company agrees to register the shares of Common Stock issued upon conversion of this Note (the “Registrable Securities”)
in a selling stockholder prospectus that shall be a part of the initial public offering registration statement. Notwithstanding
the registration obligations set forth in this Section 6, if the Securities and Exchange Commission (the “Commission”)
informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415 promulgated by the
Commission pursuant to the Securities Act of 1933, as amended, as such Rule may be amended or interpreted from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule,
be registered for resale along with the shares of Common Stock being offered in the initial public offering (or any other securities
that may also be offered in the initial public offering and included on the registration statement) on a single registration statement,
the Company agrees to, within twenty-four (24) hours, inform the Holder and will file a new registration statement within thirty
(30) calendar days following consummation of the initial public offering to register for resale the Registrable Securities.”

 

7.          The
undersigned hereby acknowledges, ratifies and confirms in all respects the Prior Amendments.         

 

8.          Within
three (3) days of execution of this Amended Fifth Consent, the Company will issue to the December 2014 Purchasers additional Warrants
in the amounts described on Schedule A hereto.

 

9.          Notwithstanding
any other documents executed by the Purchaser prior to this Amended Fifth Consent, the Purchaser acknowledges and agrees that this
Amended Fifth Consent constitutes the sole agreement between the parties relating to the consummation of a Qualified Offering.

 

10.         The
undersigned represents to the Company that it is the holder of the Notes and Warrants in the amounts set forth on Schedule A
hereto, it has not sold, transferred or otherwise assigned any of the Notes and Warrants and it has the authority to enter into
and deliver this Amended Fifth Consent.

 

11.         The
Company represents that Schedule A hereto identifies all of the holders and sets forth the amounts as of the date herein
of all of the securities issued or issuable pursuant to the Securities Purchase Agreements and that the Transaction Documents have
not been previously amended nor any waiver of any term thereof granted by any party thereto other than as set forth in the Prior
Amendments and this Amended Fifth Consent.

 

12.         This
Amended Fifth Consent may be executed in counterparts, each of which shall be deemed an original but all of which shall together
constitute one and the same instrument. This Amended Fifth Consent may be signed and delivered by facsimile or electronically and
such facsimile or electronically signed and delivered Amended Fifth Consent shall be enforceable.

 

    	 	3	 

     

    

 

 

13.         This
Amended Fifth Consent shall be included in the definition of Transaction Documents as such term is defined in the Securities Purchase
Agreements.

 

14.         Sections
5.4, 5.5, 5.12 and 5.21 of the Securities Purchase Agreements are incorporated herein by reference.

 

15.         Except
as expressly set forth herein, this Amended Fifth Consent shall not be deemed to be a waiver, amendment or modification of
any provisions of the Transaction Documents or of any right, power or remedy of the Purchaser, or constitute a waiver
of any provision of the Transaction Documents (except to the extent herein set forth), or any other document, instrument and/or
agreement executed or delivered in connection therewith and any other agreement to which the Purchaser may be parties to, in each
case whether arising before or after the date hereof or as a result of performance hereunder or thereunder. Except as set forth
herein, the Purchaser reserves all rights, remedies, powers, or privileges available under the Transaction Documents
and any other agreement to which the Purchaser may be parties to, at law or otherwise. This Amended Fifth Consent shall not
constitute a novation or satisfaction and accord of the Transaction Documents or any other document, instrument and/or agreement
executed or delivered in connection therewith and any other agreement to which the Purchaser may be a party to.

 

(Signatures to follow)

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF, the Company and the
undersigned Purchasers have caused this Fifth Consent to be executed as of the date first written above.

 

	 	ACCELERATED PHARMA, INC.
	 	the “Company”
	 	 	 
	 	By:	 
	 	 	Michael Fonstein, Chief Executive Officer

 

“PRIOR
PURCHASER”

 

Name of Prior Purchaser:
____________________________________________________________________________

 

Signature of Authorized Signatory of
Prior Purchaser: ______________________________________________________

 

Name of Authorized Signatory: _______________________________________________________________________

 

Title of Authorized Signatory: ________________________________________________________________________

 

    	 	5	 

     

    

 

Exhibit A

List of Prior Purchasers

  

SCHEDULE A 

 

	PURCHASERS OF DECEMBER 23, 2014	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 	 	FIFTH
 CONSENT
 WARRANTS	 
	CURBER INTERNATIONAL LTD.
 William House, 2nd Floor
 Hibiscus Square, Pond Street
 P.O. Box 156
 Grand Turk Truks and Caicos Island
 Attn: M. Goldschmid
 Mgoldshmid48@gmail.com
	 	$	400,000.00	 	 	 	27,778	 	 	 	2,779	 
	MORRIS FUCHS
 1109 East 22nd Street
 Brooklyn, New York 11210
 Email: lenoxxmorris@aol.com
	 	$	50,000.00	 	 	 	3,472	 	 	 	347	 
	NACHUM STEIN
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	100,000.00	 	 	 	6,944	 	 	 	694	 
	AMERICAN EUROPEAN INSURANCE CO.
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	100,000.00	 	 	 	6,944	 	 	 	694	 
	HSI PARTNERSHIP
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	50,000.00	 	 	 	3,472	 	 	 	347	 
	RR INVESTMENT 2012 LP
 c/o Ken Gliedman
 Licht Gliedman Investments PC
 551 5th Avenue
 New York, NY 10176
	 	$	50,000.00	 	 	 	3,472	 	 	 	347	 
	TOTALS	 	$	750,000.00	 	 	 	52,082	 	 	 	5,208	 

 

    1 

     

    

  

SCHEDULE A (continued)

 

	PURCHASERS OF MAY 8, 2015 AND JUNE 11, 2015	 	PURCHASE
                                         PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE 
	 	 	WARRANTS	 
	2004 LEON SCHARF IRREVOCABLE TRUST CORP. 
3839 Flatlands Ave., Suite 201 
Brooklyn, NY 11234 
Attn: Willy Beer 
Tax ID# 20-665-6152	 	$	100,000.00	 	 	 	50,000	 
	HOCH FAMILY EQUITIES LLC 
125-10 Queens Boulevard, Suite 224 
Kew Gardens, NY 11415 
Attn: Joseph Hoch, Member 
Tax ID# 263694206	 	$	50,000.00	 	 	 	25,000	 
	RR INVESTMENT 2012 LP 
285 Central Park West 
New York, NY 10024 
Attn: Ralph Rieder,
    Manager 
Tax ID# 30-0759589	 	$	500,000.00	 	 	 	250,000	 
	API BIO INVESTORS, LLC 
7 Glenwood Avenue, Suite 4190 
East Orange, NJ 07017 
Attn:
    AJ Ginsburg, Member 
AJginsburg12@gmail.com 
Tax ID# 47-3876371	 	$	340,000.00	 	 	 	170,000	 
	ABRAHAM BELSKY 
16 Boxwood Lane 
Lawrence, NY 11559 
Fax: 718 313-9880 
Tax ID# ###-##-####	 	$	50,000.00	 	 	 	25,000	 
	EDWIN W. COLMAN CHILDREN’S TRUST 
50 Adams Gulch Road 
Ketchum, ID 83340 
Attn:
    Robert S. Colman, Trustee 
Email: bcolman@colman-partners.com 
Tax ID# 39-6330570	 	$	100,000.00	 	 	 	50,000	 
	ELI INZLICHT-SPREI
 1121
                                         East 21st Street
 Brooklyn,
                                         NY 11210
 Fax:
                                         718-859-5717
 Tax
                                         ID# ###-##-####
	 	$	25,000.00	 	 	 	12,500	 
	HARVEY LANG 
783 Montgomery Street 
Brooklyn, NY 11213 
Fax: 718-773-1283 
Tax ID#
    ###-##-####	 	$	25,000.00	 	 	 	12,500	 
	ALPHA CAPITAL ANSTALT 
Lettstrasse 32 
9490 Vaduz, Liechtenstein 
Attn: Konrad Ackermann,
    Director 
Fax: 011-423-2323196	 	$	750,000.00	 	 	 	375,000	 
	BRIO CAPITAL MASTER FUND LTD. 
C/O Brio Management LLC 
100 Merrick Road, Suite 401C 
Rockville
    Centre, NY 11570-4800 
Fax: 646-390-2158 
Tax ID# 98-1072321	 	$	110,000.00	 	 	 	55,000	 
	BERNHARD
                                         LAZARUS
 42
                                         Herbert Samuel St., Apt. 40
 Tel
                                         Aviv 68018, Israel
 Email:
                                         lazarusb@netvision.net.il
 Tax
                                         ID#: ###-##-####
	 	$	50,000.00	 	 	 	25,000	 
	TOTALS	 	$	2,100,000.00	 	 	 	1,050,000	 

 

    2 

     

    

 

SCHEDULE A (continued)

 

	PURCHASERS OF NOVEMBER 6, 2015	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	API BIO INVESTORS, LLC
 1 Skyline Terrace
 Spring Valley, NY 10977
 Attn: A.J. Ginsburg, Member
 Email: AJGinsburg12@gmail.com
 Tax ID#:
	 	$	220,000.00	 	 	 	6,659	 
	MORDECHAI MARC BELSKY 
270 Forest Avenue 
Woodmere, NY 11598 
Tel.: (516) 375-6000 
Tax ID# ###-##-####	 	$	50,000.00	 	 	 	1,513	 
	KEREN BROCHA 
26 Commonwealth Drive 
Lakewood, NJ 08701 
Attn: Chaim Stefansky, Manager 
Tel.: (718) 362-1634 
Tax ID#: 32-0012556	 	$	35,000.00	 	 	 	1,059	 
	CHAIM GROSS 
1980 Swarthmore Avenue, Unit 1 
Lakewood, NJ 08701 
Tel.: (732) 930-9805 
Tax ID#: ###-##-####	 	$	30,000.00	 	 	 	908	 
	HOCH FAMILY EQUITIES, LLC 
125-10 Queens Boulevard, Suite 224 
Kew Gardens, NY 11415 
Attn: Ari Hoch, Member 
Fax: (718) 374-3872 
Tax ID# 26-3694206	 	$	100,000.00	 	 	 	3,027	 
	MORRIS FUCHS
 1109 East 22nd Street
 Brooklyn, New York 11210
 Email: gcmf47@gmail.com
	 	$	50,000.00	 	 	 	1,513	 
	ELI INZLICHT-SPREI
 1121 East 21st Street
 Brooklyn, NY 11210
 Fax: 718 859-5717
 Tax ID# ###-##-####
	 	$	15,000.00	 	 	 	454	 
	TOTALS	 	$	500,000.00	 	 	 	15,133	 

 

    3 

     

    

 

SCHEDULE A (continued)

 

	PURCHASERS OF APRIL 20, 2016 and APRIL 22, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	2004 LEON SCHARF IRREVOCABLE TRUST CORP. 
3839 Flatlands Ave., Suite 201 
Brooklyn, NY 11234 
Attn: Willy Beer 
Tax ID# 20-665-6152	 	$	100,000.00	 	 	 	2,579	 
	VENTURE CAP GROUP LLC 
730 Eastern Parkway 
Brooklyn, NY 11213	 	$	50,000.00	 	 	 	1,289	 
	NACHUM STEIN
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	40,000.00	 	 	 	1,031	 
	AMERICAN EUROPEAN INSURANCE CO.
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	40,000.00	 	 	 	1,031	 
	HSI PARTNERSHIP
 444 Madison Avenue, Suite 501
 New York, NY 10022
 Email: ns11238193@aol.com
	 	$	20,000.00	 	 	 	516	 
	TOTALS	 	$	250,000.00	 	 	 	6,446	 

 

	PURCHASERS OF MAY 9, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	MANUEL S. SCHARF
 1575 50th Street, Suite 201
 Brooklyn, New York 11219
 Fax: (718) 853-5757
	 	$	100,000.00	 	 	 	2,579	 

 

	PURCHASERS OF MAY 27, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	SCHEIN VENTURES LLC 
552 Clubhouse Road 
Woodmere, New York 11598 
Attn: Joshua D. Schein, Manager	 	$	100,000.00	 	 	 	2,149	 

 

    4 

     

    

 

SCHEDULE A (continued)

 

	PURCHASERS OF JULY 15, 2016	 	PURCHASE PRICE
 AND PRINCIPAL
 AMOUNT OF NOTE	 	 	WARRANTS	 
	ALPHA CAPITAL ANSTALT 
Lettstrasse 32 
9490 Vaduz, Liechtenstein 
Attn: Konrad Ackermann, Director 
Fax: 011-423-2323196	 	$	50,000.00	 	 	 	1,074	 
	RAYMOND DAYAN
 1734 East 24th Street
 Brooklyn, New York 11229
 Fax: (212) 564-6135
	 	$	40,000.00	 	 	 	859	 
	BRIO CAPITAL MASTER FUND LTD. 
C/O Brio Management LLC 
100 Merrick Road, Suite 401C 
Rockville Centre, NY 11570-4800 
Fax: 646-390-2158 
Tax ID# 98-1072321	 	$	25,000.00	 	 	 	537	 
	EDWIN W. COLMAN CHILDREN’S TRUST 
50 Adams Gulch Road 
Ketchum, ID 83340 
Attn: Robert S. Colman, Trustee 
Email: bcolman@colman-partners.com 
Tax ID# 39-6330570	 	$	50,000.00	 	 	 	1,074	 
	2004 LEON SCHARF IRREVOCABLE TRUST CORP. 
3839 Flatlands Ave., Suite 201 
Brooklyn, NY 11234 
Attn: Willy Beer 
Tax ID# 20-665-6152	 	$	50,000.00	 	 	 	1,074	 
	TOTALS	 	$	215,000.00	 	 	 	4,618	 
	 	 	 	 	 	 	 	 	 
	Additional 2016 Purchasers	 	 	 	 	 	 
	Yuri Rabinovich 
200 E. Delaware PL, unit 4C Chicago IL 60611 
Email: amtdune@msn.com	 	$	50,000.00	 	 	 	1,074	 
	Ross Overbeek 
6317 New Albany road 
Lisle, IL 60532 
Email: ross@thefig.info	 	$	20,000.00	 	 	 	431	 
	Michael H. Schwartz Profit Sharing Plan 
Tax ID# 20-665-6152	 	$	120,000.00	 	 	 	2,578	 
	Masoud Toghraie 
2350 East Allview Terrace 
Los Angeles, CA 90068 
Email: toghraiem@earthlink.net	 	$	200,000.00	 	 	 	4,297	 
	TOTALS	 	$	390,000	 	 	 	8,380	 

 

    5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]